Fisher & Paykel Healthcare Just Fell 7% From Its All-Time High — Time to Buy the Dip?

A $22 Billion Giant Takes a Breather

Fisher & Paykel Healthcare (NZX: FPH) hit an all-time high of $41.40 NZD on March 3rd, 2026, cementing its position as one of the most valuable companies on the NZX. But since that peak, shares have dropped over 7% to around $36.41, wiping more than $1.5 billion off its market cap in just a few weeks. For investors who've been watching from the sidelines, the question is obvious: is this the pullback you've been waiting for?

What the Numbers Say

FPH's half-year results (to September 2025) were strong by any measure:

• •Revenue: $1.09 billion NZD, up 14% year-on-year (12% in constant currency)
• •Net profit after tax: $213 million NZD, up a massive 39%
• •Earnings per share: $0.36 NZD, beating analyst estimates of $0.34 by 5.3%
• •EBITDA margin: 32.2% — exceptionally healthy for a medical devices company

These aren't the numbers of a company in trouble. FPH continues to execute well, driven by growing global demand for its respiratory care products and hospital hardware.

The Valuation Question

Here's where it gets tricky. FPH trades on a trailing P/E ratio of 39.5x — that's expensive by almost any standard. For context, the NZX 50 average P/E sits around 20-25x. You're paying a significant premium for FPH's quality and growth.

Key valuation metrics:

• •Market cap: $21.9 billion NZD
• •Trailing P/E: 39.5x
• •Dividend yield: 1.18% (not a yield play)
• •Analyst consensus target: $41.98 NZD (15.3% upside from current price)

The dividend yield of 1.18% tells you this isn't an income stock. You buy FPH for growth, and the market has consistently been willing to pay up for it.

Why Analysts Are Still Bullish

Fourteen analysts cover FPH and the consensus recommendation is Buy, with an average target of $41.98 — essentially back to the all-time high. Their thesis centres on a few key themes:

• •Respiratory care is a structural growth market: Ageing populations and rising rates of obstructive sleep apnoea globally create a long runway
• •Hospital spending is recovering: Post-COVID capital expenditure budgets are being unlocked, benefiting FPH's hospital hardware division
• •Next earnings catalyst: Full-year results are due May 27, 2026, with consensus expecting EPS of $0.42 for the second half — implying full-year EPS of roughly $0.79
• •RBC Capital upgraded the stock to Sector Perform from Underperform in February 2026, removing a notable bear from the equation

What Could Go Wrong

No stock is bulletproof, and there are risks to consider:

• •Valuation compression: If global markets sell off, high-P/E stocks like FPH tend to get hit hardest. A rotation from growth to value could see the stock re-rate lower
• •Currency risk: FPH earns most of its revenue in USD and EUR. A strengthening NZD would compress reported earnings
• •Competition: ResMed and other respiratory care players are investing heavily. FPH's market share isn't guaranteed
• •The 7% drop might not be over: Stocks that hit all-time highs and pull back can sometimes retrace 15-20% before finding support

The Bottom Line

Fisher & Paykel Healthcare is one of the highest-quality companies on the NZX — strong margins, consistent earnings beats, and a global growth story in healthcare. The 7% pullback from all-time highs creates a more attractive entry point, but the stock still trades at nearly 40x earnings, so you're paying for perfection. If you have a long-term horizon and can stomach the premium valuation, FPH remains one of the best businesses in New Zealand. If you're price-sensitive, there might be a better entry point ahead — especially if global markets wobble.

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*